Government pledges additional Continuous Glucose Monitoring Subsidies for all Australians living with type 1 diabetes
21 April 2022 – Dexcom and AMSL Diabetes welcome the recent bi-partisan commitment to providing access to continuous glucose monitoring for all people with Type 1 diabetes in Australia.
Expanding the subsidy access to all people with Type 1 diabetes in Australia irrespective of their age and concession card status is an important reform that improves the equity of access to these important technologies.
Dexcom and AMSL Diabetes look forward to working with the Department of Health, Diabetes Australia, clinicians, diabetes educators, pharmacists and wholesalers on the implementation of this long-awaited reform to the National Diabetes Services Scheme.
We thank JDRF, Diabetes Australia and all those who have supported and worked for improved access to diabetes technologies for the diabetes community. Through tireless advocacy and education, they have worked toward ensuring more individuals will be able to benefit from these technologies.
To keep our support lines free for customers who require urgent technical assistance, please email us at diabetes@amsl.com.au if you would like to discuss this further. Alternatively please sign up to our newsletter available at amsldiabetes.com.au and as further updates are released, we will be sure to let everyone know.
About AMSL Diabetes
AMSL Diabetes is dedicated to helping people live well with diabetes. For over 20 years, AMSL Diabetes has given thousands of people the tools and support they need to improve their quality of life. AMSL Diabetes provides a range of diabetes products to individuals living with diabetes and the healthcare professionals that support them including t:slim X2 Insulin Pumps, Dexcom CGM Systems, OneTouch Blood Glucose Systems and other diabetes accessories. For more information, visit amsldiabetes.com.au.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit dexcom.com.
“Dexcom and AMSL Diabetes look forward to working with the Department of Health, Diabetes Australia, clinicians, diabetes educators, pharmacists and wholesalers on the implementation of this long-awaited reform to the National Diabetes Services Scheme.”
